Agios Pharmaceuticals CEO Jacqualyn Fouse receives $17M in 2019
Agios Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 16, 2020
Agios Pharmaceuticals reported fiscal year 2019 executive compensation information on April 16, 2020.
In 2019, six executives at Agios Pharmaceuticals received on average a compensation package of $5.5M, a 33% increase compared to previous year.
Average pay of disclosed executives at Agios Pharmaceuticals
Jacqualyn A. Fouse, Chief Executive Officer, received $17M in total. 78% of Fouse's compensation, or $13M, was in option awards. Fouse also received $424K in non-equity incentive plan, $665K in salary, $2.5M in stock awards, as well as $105K in other compensation.
For fiscal year 2019, the median employee pay was $267,104 at Agios Pharmaceuticals. Therefore, the ratio of Jacqualyn A. Fouse's pay to the median employee pay was 62 to one.
Andrew Hirsch, Chief Financial Officer, received a compensation package of $4.2M, which increased by 35% compared to previous year. 45% of the compensation package, or $1.9M, was in stock awards.
Christopher Bowden, Chief Medical Officer, earned $3.2M in 2019, a 3% increase compared to previous year.
Scott Biller, Chief Scientific Officer, received $3.2M in 2019, which increases by 3% compared to 2018.
Jonathan Biller, Chief Legal Officer, earned $3.2M in 2019.
David P. Schenkein, Chief Executive Officer, received $2.6M in 2019, which decreases by 69% compared to 2018.
Related executives
Jacqualyn Fouse
Agios Pharmaceuticals
Chief Executive Officer
David Schenkein
Agios Pharmaceuticals
Chief Executive Officer
Andrew Hirsch
Agios Pharmaceuticals
Chief Financial Officer
Jonathan Biller
Agios Pharmaceuticals
Chief Financial Officer
Scott Biller
Agios Pharmaceuticals
Chief Scientific Officer
Christopher Bowden
Agios Pharmaceuticals
Chief Medical Officer
You may also like
Source: SEC filing on April 16, 2020.